Nanogen Pharmaceutical Biotechnology Joint Stock Company

11 clinical trials · Sponsor

Record	Firm	Date
Pharmacokinetics, Pharmacodynamics, and Safety of NANOKINE Compared With Eprex 4000 U in Healthy Volunteers (NCT06919861)	Nanogen Pharmaceutical Biotechnology Joint Stock Company	2026-09-01
Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis (NCT05636891)	Nanogen Pharmaceutical Biotechnology Joint Stock Company	2021-09-19
Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 (NCT04922788)	Nanogen Pharmaceutical Biotechnology Joint Stock Company	2021-06-07
A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers (NCT04683484)	Nanogen Pharmaceutical Biotechnology Joint Stock Company	2020-12-10
A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD) (NCT05585645)	Nanogen Pharmaceutical Biotechnology Joint Stock Company	2019-08-08
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. (NCT05301530)	Nanogen Pharmaceutical Biotechnology Joint Stock Company	2019-05-27
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients (NCT05301010)	Nanogen Pharmaceutical Biotechnology Joint Stock Company	2018-02-02

Every clearance here is in the API, with alerts when new ones post.